In non-small-cell lung cancer (NSCLC) and various other cancers, mutations in nuclear factor erythroid 2-related factor 2 (NRF2) cause aberrant activation of NRF2 transcriptional activity, resulting in therapeutic resistance and poor survival.
The limited efficacy of cancer immunotherapy is usually attributed to suboptimal antitumor T-cell generation, as well as impaired immunological memory development. MDX-2004 is a trispecific antibody-fusion protein developed by Modex Therapeutics Inc. that targets CD3, CD28 and CD137 on human T cells, which was designed to overcome these limitations by rejuvenating the immune system and enhancing antitumor immunity.
At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers from Circle Pharma Inc. presented their recent work on developing novel compounds that specifically target cyclin D1 while avoiding the toxicity associated with targeting cyclin D3.
Researchers from Chantibody Therapeutics Inc. presented the preclinical characterization of CT-111, a trispecific antibody engineered to simultaneously target PD-1, CTLA-4, and VEGF.
Anticancer drugs that work simultaneously through multiple mechanisms are sought after because of their potential for greater efficacy and robustness to resistance. Researchers at Capital Medical University and Chinese Institutes for Medical Research generated 21 ternary hybrids containing phenylsulfonylfuroxan, b-carboline und hydroxamic acid moieties.
Arginase 1 (Arg1) is a key mediator of immune suppression, and its overexpression has been reported in multiple cancers, including renal cell carcinoma, pancreatic cancer, and head and neck cancer. However, clinical strategies aimed at inhibiting Arg1 function have achieved only limited success.
Radiopharm Theranostics Ltd. has been granted Bellberry Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human phase I trial of its KLK3-targeting radiotherapeutic, RAD-402, for the treatment of metastatic or locally advanced prostate cancer.
Signet Therapeutics founder Haisheng Zhang is betting on organoids and AI to outsmart diffuse gastric cancer and the limits of traditional “clean” drug design.
South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes. Detailed in Cell Host & Microbe on Nov. 12, 2025, the database is expected to serve as a universal platform for academia and enable “precision microbiome medicine” for the industry, Lee told BioWorld.
Shanghai Phrontline Biopharma Co. Ltd. has described antibody-drug conjugates comprising an antibody or antigen-binding fragment targeting HER2 (erbB2) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
RSS
